Background Albeit DES might be considered as a breakthrough against neointimal hyperplasia, concerns on stent thrombosis and increase incidence of in-stent restenosis after multiple DES implantations in complex, long lesions still exist. Hereby, we tried to test efficacy and safety of using PEB in long lesions followed by focal BMS implantation in a pilot multicenter study. Methods This study enrolled 16 patients with long lesions (> 30 mm) that were treated with PEB angioplasty followed by focal stenting with BMS. IVUS was performed before, after PEB and post stenting. Clinical and angiographic follow-up was done at 6 months. The primary end-point was angiographic late lumen loss. Results Patient age was 64.6 Â± 8.1 years, 15 (93.7%) were males, and 7 (43.7%) diabetics. Target vessels were most commonly the left anterior descending (6 [31.6%]) and the right coronary artery (6 [31.6%]). PEB diameter was 2.8 Â± 0.4 mm with a 31.3 Â± 8.9 mm length. Stents per patient were 2.1 Â± 0.8. No overlapping stents were deployed. Angiographic success was achieved in 100% of patients. Peri-procedural myocardial infarction occurred in 4 patients (25%). At 6 months follow-up angiography, MLD was 1.55 Â± 0.53 mm with a late loss of 0.48 Â± 0.52 mm, a binary re-stenosis rate of 2 (12.5%). Conclusion Using PEB with focal stenting by BMS proved to be a feasible, safe, and promising strategy in long coronary lesions. However larger study are needed to confirm these data.
Attenzione! Scheda prodotto non ancora validata dall'Ateneo
|Data di pubblicazione:||2017|
|Titolo:||Paclitaxel eluting balloon plus spot bare metal stenting for diffuse and very long coronary disease. (PEB-long pilot study)|
|Autori:||Rezq, Ahmed; Zoccai, Giuseppe Biondi; Latib, Azeem; Romagnoli, Enrico; Aprile, Alessandro; Amato, Andrea; Modena, Maria Grazia; Colombo, Antonio; Sangiorgi, Giuseppe|
|Digital Object Identifier (DOI):||10.1016/j.ctrsc.2017.04.001|
|Appare nelle tipologie:||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris